Decreased bacterial diversity characterizes the altered gut microbiota in patients with psoriatic arthritis, resembling dysbiosis in inflammatory bowel disease

Arthritis and Rheumatology

Volumn 67, Issue 1, 2015, Pages 128-139

  Scher, Jose U ^a   Ubeda, Carles ^b,d   Artacho, Alejandro ^c   Attur, Mukundan ^a   Isaac, Sandrine ^c   Reddy, Soumya M ^a   Marmon, Shoshana ^b   Neimann, Andrea ^b   Brusca, Samuel ^a   Patel, Tejas ^a   Manasson, Julia ^a   Pamer, Eric G ^e   Littman, Dan R ^f   Abramson, Steven B ^a  

^a NYU HOSPITAL FOR JOINT DISEASES   (United States)

^b Genomics and Health Area Foundation for the Health and Biomedical of the Community of Valencia   (Spain)

^c Gerencia FISABIO   (Spain)

^d CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID; HEXANOIC ACID; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; OSTEOCLAST DIFFERENTIATION FACTOR; PREDNISONE; RNA 16S; SECRETORY IMMUNOGLOBULIN; CYTOKINE; IMMUNOGLOBULIN A;

ADULT; ALLELE; ARTICLE; AUTOIMMUNITY; DYSBIOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HLA SYSTEM; HUMAN; IMMUNE RESPONSE; INFLAMMATORY BOWEL DISEASE; INTESTINE FLORA; MAJOR CLINICAL STUDY; MALE; MICROBIAL DIVERSITY; NATIONAL HEALTH ORGANIZATION; PSORIASIS; PSORIATIC ARTHRITIS; PYROSEQUENCING; SINGLE DRUG DOSE; SUPERNATANT; CASE CONTROL STUDY; FECES; GASTROINTESTINAL TRACT; METABOLISM; MICROBIOLOGY; MICROFLORA; MIDDLE AGED;

ADULT; ARTHRITIS, PSORIATIC; CASE-CONTROL STUDIES; CYTOKINES; DYSBIOSIS; FATTY ACIDS; FECES; FEMALE; GASTROINTESTINAL TRACT; HUMANS; IMMUNOGLOBULIN A; INFLAMMATORY BOWEL DISEASES; MALE; MICROBIOTA; MIDDLE AGED; PSORIASIS; RANK LIGAND;

EID: 84919932773     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.38892     Document Type: Article

References (45)

1. Eder L, Chandran V, Pellet F, Shanmugarajah S, Rosen CF, Bull SB, et al. Human leucocyte antigen risk alleles for psoriatic arthritis among patients with psoriasis. Ann Rheum Dis 2012; 71: 50-5.
2. Winchester R, Minevich G, Steshenko V, Kirby B, Kane D, Greenberg DA, et al. HLA associations reveal genetic heterogeneity in psoriatic arthritis and in the psoriasis phenotype. Arthritis Rheum 2012; 64: 1134-44.
3. Cua DJ, Sherlock JP,. Autoimmunity's collateral damage: gut microbiota strikes 'back'. Nat Med 2011; 17: 1055-6.
4. Van Praet L, Van den Bosch F, Mielants H, Elewaut D,. Mucosal inflammation in spondylarthritides: past, present, and future. Curr Rheumatol Rep 2011; 13: 409-15.
5. - entheseal resident T cells. Nat Med 2012; 18: 1069-76.
6. Van Praet L, Van den Bosch FE, Jacques P, Carron P, Jans L, Colman R, et al. Microscopic gut inflammation in axial spondyloarthritis: a multiparametric predictive model. Ann Rheum Dis 2013; 72: 414-7.
7. Rath HC, Herfarth HH, Ikeda JS, Grenther WB, Hamm TE Jr, Balish E, et al. Normal luminal bacteria, especially Bacteroides species, mediate chronic colitis, gastritis, and arthritis in HLA-B27/human β2 microglobulin transgenic rats. J Clin Invest 1996; 98: 945-53.
8. Ruutu M, Thomas G, Steck R, Degli-Esposti MA, Zinkernagel MS, Alexander K, et al. β-glucan triggers spondylarthritis and Crohn's disease-like ileitis in SKG mice. Arthritis Rheum 2012; 64: 2211-22.
9. Orchard TR, Wordsworth BP, Jewell DP,. Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history. Gut 1998; 42: 387-91.
10. Scarpa R, Manguso F, D'Arienzo A, D'Armiento FP, Astarita C, Mazzacca G, et al. Microscopic inflammatory changes in colon of patients with both active psoriasis and psoriatic arthritis without bowel symptoms. J Rheumatol 2000; 27: 1241-6.
11. Li WQ, Han JL, Chan AT, Qureshi AA,. Psoriasis, psoriatic arthritis and increased risk of incident Crohn's disease in US women. Ann Rheum Dis 2013; 72: 1200-5.
12. Scher JU, Sczesnak A, Longman RS, Segata N, Ubeda C, Bielski C, et al. Expansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritis. Elife 2013; 2: e01202.
13. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H, and the CASPAR Study Group. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006; 54: 2665-73.
14. Scher JU, Ubeda C, Equinda M, Khanin R, Buischi Y, Viale A, et al. Periodontal disease and the oral microbiota in new-onset rheumatoid arthritis. Arthritis Rheum 2012; 64: 3083-94.
15. Sheneman L, Evans J, Foster JA,. Clearcut: a fast implementation of relaxed neighbor joining. Bioinformatics 2006; 22: 2823-4.
16. Nielsen OH, Gionchetti P, Ainsworth M, Vainer B, Campieri M, Borregaard N, et al. Rectal dialysate and fecal concentrations of neutrophil gelatinase-associated lipocalin, interleukin-8, and tumor necrosis factor-α in ulcerative colitis. Am J Gastroenterol 1999; 94: 2923-8.
17. Segata N, Izard J, Waldron L, Gevers D, Miropolsky L, Garrett WS, et al. Metagenomic biomarker discovery and explanation. Genome Biol 2011; 12: R60.
18. Scurati M,. Learning Bayesian networks with the bnlearn R package. J Stat Softw 2010; 35: 1-22.
19. lo precursors are the master fusogens. J Cell Physiol 2010; 223: 76-83.
20. Reveille JD,. Genetics of spondyloarthritis: beyond the MHC. Nat Rev Rheumatol 2012; 8: 296-304.
21. Mielants H, Veys EM, Cuvelier C, De Vos M, Goemaere S, De Clercq L, et al. The evolution of spondyloarthropathies in relation to gut histology. II. Histological aspects. J Rheumatol 1995; 22: 2273-8.
22. Ciccia F, Accardo-Palumbo A, Alessandro R, Rizzo A, Principe S, Peralta S, et al. Interleukin-22 and interleukin-22-producing NKp44+ natural killer cells in subclinical gut inflammation in ankylosing spondylitis. Arthritis Rheum 2012; 64: 1869-78.
23. Stebbings S, Munro K, Simon MA, Tannock G, Highton J, Harmsen H, et al. Comparison of the faecal microflora of patients with ankylosing spondylitis and controls using molecular methods of analysis. Rheumatology (Oxford) 2002; 41: 1395-401.
24. Manichanh C, Rigottier-Gois L, Bonnaud E, Gloux K, Pelletier E, Frangeul L, et al. Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach. Gut 2006; 55: 205-11.
25. Collado MC, Derrien M, Isolauri E, de Vos WM, Salminen S,. Intestinal integrity and Akkermansia muciniphila, a mucin-degrading member of the intestinal microbiota present in infants, adults, and the elderly. Appl Environ Microbiol 2007; 73: 7767-70.
26. Arumugam M, Raes J, Pelletier E, Le Paslier D, Yamada T, Mende DR, et al. Enterotypes of the human gut microbiome. Nature 2011; 473: 174-80.
27. Png CW, Linden SK, Gilshenan KS, Zoetendal EG, McSweeney CS, Sly LI, et al. Mucolytic bacteria with increased prevalence in IBD mucosa augment in vitro utilization of mucin by other bacteria. Am J Gastroenterol 2010; 105: 2420-8.
28. Vigsnaes LK, Brynskov J, Steenholdt C, Wilcks A, Licht TR,. Gram-negative bacteria account for main differences between faecal microbiota from patients with ulcerative colitis and healthy controls. Benef Microbes 2012; 3: 287-97.
29. Rajilic-Stojanovic M, Shanahan F, Guarner F, de Vos WM,. Phylogenetic analysis of dysbiosis in ulcerative colitis during remission. Inflamm Bowel Dis 2013; 19: 481-8.
30. Willing BP, Dicksved J, Halfvarson J, Andersson AF, Lucio M, Zheng Z, et al. A pyrosequencing study in twins shows that gastrointestinal microbial profiles vary with inflammatory bowel disease phenotypes. Gastroenterology 2010; 139: 1844-54.
31. Morgan XC, Tickle TL, Sokol H, Gevers D, Devaney KL, Ward DV, et al. Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol 2012; 13: R79.
32. Joossens M, Huys G, Cnockaert M, De Preter V, Verbeke K, Rutgeerts P, et al. Dysbiosis of the faecal microbiota in patients with Crohn's disease and their unaffected relatives. Gut 2011; 60: 631-7.
33. Smith PM, Howitt MR, Panikov N, Michaud M, Gallini CA, Bohlooly Y, et al. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science 2013; 341: 569-73.
34. Garner CE, Smith S, de Lacy CB, White P, Spencer R, Probert CS, et al. Volatile organic compounds from feces and their potential for diagnosis of gastrointestinal disease. FASEB J 2007; 21: 1675-88.
35. De Preter V, Machiels K, Joossens M, Arijs I, Matthys C, Vermeire S, et al. Faecal metabolite profiling identifies medium-chain fatty acids as discriminating compounds in IBD. Gut 2014. E-pub ahead of print.
36. Liberato MV, Nascimento AS, Ayers SD, Lin JZ, Cvoro A, Silveira RL, et al. Medium chain fatty acids are selective peroxisome proliferator activated receptor (PPAR) γ activators and pan-PPAR partial agonists. PLoS One 2012; 7: e36297.
37. Bassaganya-Riera J, Viladomiu M, Pedragosa M, De Simone C, Carbo A, Shaykhutdinov R, et al. Probiotic bacteria produce conjugated linoleic acid locally in the gut that targets macrophage PPAR γ to suppress colitis. PLoS One 2012; 7: e31238.
38. Bassaganya-Riera J, Hontecillas R, Horne WT, Sandridge M, Herfarth HH, Bloomfeld R, et al. Conjugated linoleic acid modulates immune responses in patients with mild to moderately active Crohn's disease. Clin Nutr 2012; 31: 721-7.
39. Chandran V, Cook RJ, Edwin J, Shen H, Pellett FJ, Shanmugarajah S, et al. Soluble biomarkers differentiate patients with psoriatic arthritis from those with psoriasis without arthritis. Rheumatology (Oxford) 2010; 49: 1399-405.
40. Xue Y, Jiang L, Cheng Q, Chen H, Yu Y, Lin Y, et al. Adipokines in psoriatic arthritis patients: the correlations with osteoclast precursors and bone erosions. PLoS One 2012; 7: e46740.
41. Ritchlin CT, Haas-Smith SA, Li P, Hicks DG, Schwarz EM,. Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest 2003; 111: 821-31.
42. Toberer F, Sykora J, Gottel D, Ruland V, Hartschuh W, Enk A, et al. Tissue microarray analysis of RANKL in cutaneous lupus erythematosus and psoriasis. Exp Dermatol 2011; 20: 600-2.
43. Knoop KA, Kumar N, Butler BR, Sakthivel SK, Taylor RT, Nochi T, et al. RANKL is necessary and sufficient to initiate development of antigen-sampling M cells in the intestinal epithelium. J Immunol 2009; 183: 5738-47.
44. Moschen AR, Kaser A, Enrich B, Ludwiczek O, Gabriel M, Obrist P, et al. The RANKL/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss. Gut 2005; 54: 479-87.
45. Elinav E, Strowig T, Kau AL, Henao-Mejia J, Thaiss CA, Booth CJ, et al. NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis. Cell 2011; 145: 745-57.